MaxCyte Overview
- Founded
-
1998
- Status
-
Public
- Employees
-
84
- Stock Symbol
-
MXCT
- Share Price
-
$5.76
- (As of Friday Closing)
MaxCyte General Information
Description
MaxCyte Inc operates in the United States healthcare sector. It develops proprietary electroporation technology, which used blood cells instead of traditional chemical methods to transport medical gene therapies to targeted sites, increasing their safety and efficacy. The company technology finds its use in biotechnology and pharmaceutical firms engaged in cell therapy, including gene editing and immuno-oncology and in drug discovery, development, and biomanufacturing. Its products include MaxCyte STX, VLX, and GT. The company application includes Cell/Gene Therapy, Protein Production, Cell-based Assays, Gene Editing, Cell Line Development, and Viral Vectors/Vaccines. It acquires its income principally from the sale or lease of instruments and processing assemblies.
Contact Information
Website
www.maxcyte.com
Formerly Known As
TheraMed
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
LON
Primary Office
- 22 Firstfield Road
- Suite 110
- Gaithersburg, MD 20878
- United States
+1 (301) 000-0000
MaxCyte Timeline
MaxCyte Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $5.76 | $5.87 | $3.46 - $17.09 | $586M | 102M | 47.2K | -$0.20 |
MaxCyte Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 274,360 | 772,035 | 523,497 | 79,149 |
| Revenue | 41,486 | 33,894 | 26,169 | 21,621 |
| EBITDA | (18,479) | (16,765) | (10,009) | (11,806) |
| Net Income | (19,882) | (19,082) | (11,816) | (12,895) |
| Total Assets | 289,777 | 284,120 | 51,780 | 29,985 |
| Total Debt | 14,492 | 5,682 | 6,966 | 7,211 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
MaxCyte Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
MaxCyte Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
MaxCyte Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
MaxCyte Inc operates in the United States healthcare sector. It develops proprietary electroporation technology, which u
Drug Discovery
Gaithersburg, MD
84
As of 2021
00000
000000000
00000
000 00
t labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris
0000000000000
Johnson City, TN
000000000000
000000
consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut
0000 000000000
Menlo Park, CA
000
As of 0000
00000
0000
0000-00-00
00000000
00000
Add Comparison
MaxCyte Competitors (25)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| PPA Research Group | Private Equity-Backed | Johnson City, TN | 000000000000 | |||
| 0000000000 | Formerly VC-backed | Menlo Park, CA | 000 | 00000 | 00000000 | 00000 |
| 0000000 | Formerly VC-backed | Redwood City, CA | 000 | 00000 | 000000 - 000 | 00000 |
| 00000 | Corporation | San Diego, CA | 00 | 00000 | 00000000 | 00000 |
| 00000000 | Formerly VC-backed | San Diego, CA | 00000 | 00000 | 000000&0 |
MaxCyte Patents
MaxCyte Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210348109-A1 | Systems and methods for electroporation | Pending | 11-May-2020 | 000000000 | |
| CA-2982759-A1 | Methods and compositions for modifying genomic dna | Pending | 13-Apr-2015 | 0000000000 | |
| EP-3283635-A1 | Methods and compositions for modifying genomic dna | Granted | 13-Apr-2015 | 0000000000 | |
| JP-2018512162-A | Methods and compositions for modifying genomic dna | Granted | 13-Apr-2015 | 0000000000 | |
| US-20180112235-A1 | Methods and compositions for modifying genomic dna | Pending | 13-Apr-2015 | C12N15/907 |
MaxCyte Executive Team (18)
MaxCyte Board Members (14)
| Name | Representing | Role | Since |
|---|---|---|---|
| Arthur Mandell | Self | Board Member | 000 0000 |
| Douglas Doerfler | MaxCyte | Founder, Chief Executive Officer, President & Board Member | 000 0000 |
| J. Thompson Ph.D | MaxCyte | Chairman & Board Member | 000 0000 |
| John Johnston | MaxCyte | Board Member | 000 0000 |
| Rekha Hemrajani | Self | Board Member | 000 0000 |
MaxCyte Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
MaxCyte Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|